LAUSR

Purpose of ReviewA growing body of research highlights the use of TNF inhibitors in the treatment of psoriasis and psoriatic arthritis. We aim to review the literature, compile psoriasis efficacy data for TNF inhibitors, and offer advice regarding the approach to treating this condition.Recent FindingsThe results of randomized placebo-controlled studies indicate that TNF inhibitors are efficacious and well tolerated in the treatment of psoriasis. There is a greater prevalence of anxiety, depression, cardiovascular disease, obesity, diabetes, hypertension, dyslipidemia, fatty liver disease, metabolic syndrome, and inflammatory bowel disease in psoriasis patients than in the general population. Severe psoriasis portends an increased risk of mortality.SummaryAlthough patients with mild-to-moderate psoriasis do not have an increased mortality rate, the inherent inflammatory nature of psoriasis and its association with serious comorbid conditions may warrant the use of systemic medications, such as TNF inhibitors.